Nebenwirkungen · Hirobriz Breezhaler
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules · Abschnitt 4.8 · PDF-Seite 6
HOS-212880 · Präparat HOS-154998
The Hirobriz Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD. 4 764 patients were exposed to indacaterol up to one year at doses up to twice the maximum recommended dose. Of these patients, 2 611 were on treatment with 150 microgram once daily and 1 157 on treatment with 300 microgram once daily. Approximately 41% of patients had severe COPD. The mean age of patients was 64 years, with 48% of patients aged 65 years or older, and the majority (80%) was Caucasian.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T02:00:00Z · SHA-256 fb81a28f0d9f6b6fc71b5d074e281a0775bb793c603e9e81fc4de43eb7f5ea56 · Passage 815c5ae795e59a1a3e5e58e60ec5a4bb317612c4f7f9d94986a2663a4f8a90f0 · Zeichen 1012–1553 im Abschnitt